Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Myovant Ready To File Relugolix For Prostate Cancer

Nov 19 2019

• By Joseph Haas

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours — Myovant now is on pace for two FDA filings of relugolix in 2020

Related Content

Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

May 14 2019

Takeda Continues To Shed Pipeline Assets In Roivant Deal

Jun 07 2016

Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

Jul 23 2019

AbbVie Revs Up The Race To Market In Uterine Fibroids

Aug 05 2019

Gene Therapy 'Vant' Unveiled As Dainippon, Roivant Finalize $3bn Deal

Nov 06 2019

Related Companies

Myovant Sciences Ltd.

AbbVie Inc.

Takeda Pharmaceutical Co. Ltd.

Medivation, Inc.

Sumitomo Pharma Co., Ltd.

Roivant Sciences Ltd.

Additional Topics

Clinical Trials Drug Approval Standards Business Strategies Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window